FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W828532425> ?p ?o ?g. }

• W828532425 abstract "Abstract Introduction Hemophagocytic lymphohistiocytosis (HLH), also known as hemophagocytic syndrome (HPS) is characterized by cytokines storm and uncontrolled activation of macrophages. Secondary HLH in adults may occur in different occasions, including infections, autoimmune diseases, carcinomas and hematologic malignancies, in which Lymphoma-associated hemophagocytic lymphohistiocytosis(LA-HLH) has a high fatality rate and the worst outcome. The major cause of LA-HLH is aggressive non-Hodgkin's lymphoma (NHL), especially T/NKT cell lymphomas. Until now, there is no recommended therapeutic schedule for this fatal disease. Because of promising results of etoposide-containing regimen for HLH and high effective of continuous infusion chemotherapy regimen for aggressive NHL .The investigators therefore employed an intensive chemotherapy regimen--DA-EPOCH regimen (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) to treat non-Hodgkin's lymphoma with hemophagocytic lymphohistiocytosis and we have performed a preliminary analysis of this ongoing Phase 2 study and evaluated safety and efficacy of this regimen. Methods The clinical trial was designed as a prospective, multicenter, single-arm phase 2 clinical trial (NCT01818908). Enrolled patients included those with previously untreated NHL, and met the diagnostic criteria of either HLH2004 or ASH 2009 of HLH, patients with primary HLH and secondary HLH other than NHL were excluded. Therapeutic protocol of DA-EPOCH regimen was as follows: etoposide 50 mg/m2 CI 24h d1-d4, doxorubicin 10 mg/m2 CI 24h d1-d4, vincristine 0.4 mg/m2 CI 24h d1-d4, cyclophosphamide 750 mg/m2 IV d5, prednisone 60 mg/m2 oral d1-d5, If enrolled patient was histologically confirmed CD20+ B cell lymphoma, standard dose of rituximab will be recommended to combine with DA-EPOCH regimen. Drug dose was adjusted as previously described (Wyndham H. et al, 2002), each cycle of treatment was administered every 21 to 28 days according to recovery of toxicities. For patients who responded to the treatment and did not have disease progression, interim evaluation was conducted after 3 cycles of treatment. Results At the time of analysis 26 patients were enrolled and 20 patients were eligible to evaluate. Patients were 60.0% (12/20) male with median age 44(range: 14-60), the age-adjusted international prognostic score (aaIPI) enrolled to study was high/intermediate (2 score) 10/20, high risk group (3 score) 10/20. Histologies were four B-NHL, ten T-NHL and six NK-NHL. The median number of cycles of therapy was 3, patients who had discontinued study were mainly due to rapid disease progression. The overall response rate (ORR) among treated pts was 50.0%, with 35.0% (7/20) of patients achieving CR/CRu and 15.0% (3/20) achieving PR, and 50.0% of patients (10/20) had PD. With the median follow-up of 8 months, progression-free survival (PFS) rate was 46.3% and in subgroup analysis, PFS of B-NHL, T-NHL and NK-NHL was 75%, 45.7% and 25% respectively (Fig. 1); Overall survival (OS) rate was 52.4%(Fig. 2) and 75.0%, 58.3%, 22.2% in subgroup of B-NHL, T-NHL and NK-NHL(Fig. 3). The most common grade ≥3 treatment-related side effects were hematologic toxicities including neutropenia and thrombocytopenia. Conclusions Lymphoma-associated hemophagocytic lymphohistiocytosis progresses rapidly and has a high mortality rate, our preliminary results suggest DA-EPOCH regimen has acceptable toxicities and promising activity in NHL with HLH, especially for B-NHL and T-NHL, but prognosis of NK-NHL with HLH remains dismal, urgent need for novel therapeutic strategies may benefit the survival of patients with this disease. Disclosures: No relevant conflicts of interest to declare." @default.
• W828532425 created "2016-06-24" @default.
• W828532425 creator A5003246532 @default.
• W828532425 creator A5004035854 @default.
• W828532425 creator A5012278873 @default.
• W828532425 creator A5018447011 @default.
• W828532425 creator A5021032631 @default.
• W828532425 creator A5028012876 @default.
• W828532425 creator A5029391631 @default.
• W828532425 creator A5040795581 @default.
• W828532425 creator A5053654026 @default.
• W828532425 creator A5063900505 @default.
• W828532425 creator A5071211303 @default.
• W828532425 date "2013-11-15" @default.
• W828532425 modified "2023-09-28" @default.
• W828532425 title "Clinical Study Of Dose-Adjusted EPOCH Regimen For Non-Hodgkin's Lymphoma With Hemophagocytic Lymphohistiocytosis: Preliminary Results Of An Ongoing Phase II Study" @default.
• W828532425 doi "https://doi.org/10.1182/blood.v122.21.4360.4360" @default.
• W828532425 hasPublicationYear "2013" @default.
• W828532425 type Work @default.
• W828532425 sameAs 828532425 @default.
• W828532425 citedByCount "0" @default.
• W828532425 crossrefType "journal-article" @default.
• W828532425 hasAuthorship W828532425A5003246532 @default.
• W828532425 hasAuthorship W828532425A5004035854 @default.
• W828532425 hasAuthorship W828532425A5012278873 @default.
• W828532425 hasAuthorship W828532425A5018447011 @default.
• W828532425 hasAuthorship W828532425A5021032631 @default.
• W828532425 hasAuthorship W828532425A5028012876 @default.
• W828532425 hasAuthorship W828532425A5029391631 @default.
• W828532425 hasAuthorship W828532425A5040795581 @default.
• W828532425 hasAuthorship W828532425A5053654026 @default.
• W828532425 hasAuthorship W828532425A5063900505 @default.
• W828532425 hasAuthorship W828532425A5071211303 @default.
• W828532425 hasConcept C121332964 @default.
• W828532425 hasConcept C126322002 @default.
• W828532425 hasConcept C1276947 @default.
• W828532425 hasConcept C141071460 @default.
• W828532425 hasConcept C143998085 @default.
• W828532425 hasConcept C150846664 @default.
• W828532425 hasConcept C2776694085 @default.
• W828532425 hasConcept C2776755627 @default.
• W828532425 hasConcept C2778119113 @default.
• W828532425 hasConcept C2778336483 @default.
• W828532425 hasConcept C2778720950 @default.
• W828532425 hasConcept C2779079688 @default.
• W828532425 hasConcept C2779134260 @default.
• W828532425 hasConcept C2779338263 @default.
• W828532425 hasConcept C2779429289 @default.
• W828532425 hasConcept C2780317896 @default.
• W828532425 hasConcept C2780653079 @default.
• W828532425 hasConcept C2781214270 @default.
• W828532425 hasConcept C2781413609 @default.
• W828532425 hasConcept C71924100 @default.
• W828532425 hasConcept C90924648 @default.
• W828532425 hasConceptScore W828532425C121332964 @default.
• W828532425 hasConceptScore W828532425C126322002 @default.
• W828532425 hasConceptScore W828532425C1276947 @default.
• W828532425 hasConceptScore W828532425C141071460 @default.
• W828532425 hasConceptScore W828532425C143998085 @default.
• W828532425 hasConceptScore W828532425C150846664 @default.
• W828532425 hasConceptScore W828532425C2776694085 @default.
• W828532425 hasConceptScore W828532425C2776755627 @default.
• W828532425 hasConceptScore W828532425C2778119113 @default.
• W828532425 hasConceptScore W828532425C2778336483 @default.
• W828532425 hasConceptScore W828532425C2778720950 @default.
• W828532425 hasConceptScore W828532425C2779079688 @default.
• W828532425 hasConceptScore W828532425C2779134260 @default.
• W828532425 hasConceptScore W828532425C2779338263 @default.
• W828532425 hasConceptScore W828532425C2779429289 @default.
• W828532425 hasConceptScore W828532425C2780317896 @default.
• W828532425 hasConceptScore W828532425C2780653079 @default.
• W828532425 hasConceptScore W828532425C2781214270 @default.
• W828532425 hasConceptScore W828532425C2781413609 @default.
• W828532425 hasConceptScore W828532425C71924100 @default.
• W828532425 hasConceptScore W828532425C90924648 @default.
• W828532425 hasLocation W8285324251 @default.
• W828532425 hasOpenAccess W828532425 @default.
• W828532425 hasPrimaryLocation W8285324251 @default.
• W828532425 hasRelatedWork W2035678502 @default.
• W828532425 hasRelatedWork W2038296089 @default.
• W828532425 hasRelatedWork W2071239138 @default.
• W828532425 hasRelatedWork W2405898030 @default.
• W828532425 hasRelatedWork W2501964277 @default.
• W828532425 hasRelatedWork W2547967099 @default.
• W828532425 hasRelatedWork W2557062468 @default.
• W828532425 hasRelatedWork W2560299325 @default.
• W828532425 hasRelatedWork W2560406235 @default.
• W828532425 hasRelatedWork W2571254774 @default.
• W828532425 hasRelatedWork W2581448009 @default.
• W828532425 hasRelatedWork W2581871698 @default.
• W828532425 hasRelatedWork W2586530523 @default.
• W828532425 hasRelatedWork W2587866472 @default.
• W828532425 hasRelatedWork W2588069722 @default.
• W828532425 hasRelatedWork W2588498504 @default.
• W828532425 hasRelatedWork W3040245446 @default.
• W828532425 hasRelatedWork W3163996714 @default.
• W828532425 hasRelatedWork W3177369227 @default.
• W828532425 hasRelatedWork W3206395054 @default.
• W828532425 isParatext "false" @default.
• W828532425 isRetracted "false" @default.

• next